{"name":"Centro de Atencion e Investigacion Medica","slug":"centro-de-atencion-e-investigacion-medica","ticker":"","exchange":"","domain":"","description":"Centro de Atencion e Investigacion Medica is a pharmaceutical company focused on the research, development, and commercialization of innovative treatments. The company has a portfolio of six marketed drugs, including Theralite® and Eltrombopag (EPAG), which are used in various therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Revolade®","genericName":"Revolade®","slug":"revolade","indication":"Chronic immune thrombocytopenia (ITP)","status":"marketed"},{"name":"Eltrombopag (EPAG)","genericName":"Eltrombopag (EPAG)","slug":"eltrombopag-epag","indication":"Chronic immune thrombocytopenia (ITP)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Rivotril®","genericName":"Rivotril®","slug":"rivotril","indication":"Other","status":"marketed"},{"name":"Theralite®","genericName":"Theralite®","slug":"theralite","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Actilitio®","genericName":"Actilitio®","slug":"actilitio","indication":"Non-small cell lung cancer, PD-L1 positive","status":"marketed"}]}],"pipeline":[{"name":"Revolade®","genericName":"Revolade®","slug":"revolade","phase":"marketed","mechanism":"Revolade (eltrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow progenitor cells.","indications":["Chronic immune thrombocytopenia (ITP)","Thrombocytopenia in patients with chronic hepatitis C","Severe aplastic anemia"],"catalyst":""},{"name":"Actilitio®","genericName":"Actilitio®","slug":"actilitio","phase":"marketed","mechanism":"Actilitio is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma","Urothelial carcinoma","Renal cell carcinoma","Gastric cancer"],"catalyst":""},{"name":"Eltrombopag (EPAG)","genericName":"Eltrombopag (EPAG)","slug":"eltrombopag-epag","phase":"marketed","mechanism":"Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.","indications":["Chronic immune thrombocytopenia (ITP)","Thrombocytopenia associated with chronic hepatitis C","Severe aplastic anemia"],"catalyst":""},{"name":"Rivotril®","genericName":"Rivotril®","slug":"rivotril","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Theralite®","genericName":"Theralite®","slug":"theralite","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQalZwc2tic3BhQ3VwSnp1amRVWExiVV9feDFaVWhGS2tFVWtwNWZJVmlPVHhCWk5xRWhwU1pPc1BudS1seWNPZlczYzJLUGlHMmh0UUpOaFhnLTFTSGpFMk8wY0hxNjFINXE5YTRzWGdpX2Y2Q1FibnljOU9SdzVJcEdzREJUVGYyTVh5cmZiR0JNQ2JLYnluY3k5NExMVnJKenZWam50MXVtMGlmVkdJSmg5dFpEQlRrWHFIZEJRQzVZbFRaeVRCMF9KRE5mUQ?oc=5","date":"2026-02-25","type":"pipeline","source":"KFF Health News","summary":"En batalla por fondos, demócratas denuncian falta de atención médica para detenidos por el ICE - KFF Health News","headline":"En batalla por fondos, demócratas denuncian falta de atención médica para detenidos por el ICE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQRzc3QVVLMWR0TXF2bENUQzRkRTB5bmY4MXdLZWpwSTFxbjdXVXd1MXk3UTdTUXhwMGNWZDRQT2JpRThrN1d1MnNTcGZOLWdVdHc0ZUgzOG1saWxOODFQT3ZBenhxS1oySkVlSHExNGx4Q2JBQk1EdkY3THJxc0dlWjhoQ05RMmJvbUNwODQzczdTZjRtSXJGbDMyUFItMG9nMHdHT0gzU0l5cDJXM1NlZVNuSHdRZmFpRUpNZFdfZURjNUc0R2M3cg?oc=5","date":"2026-02-12","type":"pipeline","source":"Salud con lupa","summary":"El Estado compró más de 140 mil medicamentos oncológicos defectuosos que acabaron en la basura - Salud con lupa","headline":"El Estado compró más de 140 mil medicamentos oncológicos defectuosos que acabaron en la basura","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQeGMtdGk0TGJRZzZKaGE3MF82c2VoaE11X3pKbGFHRm1mOUVzWkR3eGdrOVFJOUZHbGJ1MGVQbkk5R3pybWJUS0I2aVdEWThiUE9hQWFNNF9KSVl5UEl1U3owNThGRlhWbUVRZ1FQd3RpcllkR1NESTZCNFVLNTBUNkNPSEk?oc=5","date":"2020-04-15","type":"trial","source":"Clinical Trials Arena","summary":"PanAmerican Clinical Research and CAIMED partner for clinical site alliance - Clinical Trials Arena","headline":"PanAmerican Clinical Research and CAIMED partner for clinical site alliance","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}